RBC Capital raised the firm’s price target on Sage Therapeutics to $63 from $60 and keeps an Outperform rating on the shares. The company’s launch plan for Zuranolone continues to be refined, and there is a high – 75%-80% – probability of approval that is further de-risked by the recent announcement of no AdComm meeting, the analyst tells investors in a research note. RBC adds that it expects significant initial uptake of zuranolone with differentiation in rapidity of effect and clean safety.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Is SAGE a Buy, Before Earnings?
- Sage Therapeutics participates in a conference call hosted by Piper Sandler
- RBC upgrades Sage Therapeutics on doctor survey, share selloff
- Sage Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
- No ad com suggests positive potential outcome for Sage’s zura, says BofA